3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
48
Arthralgia
3
Advanced Breast Cancer
3
Polycystic Ovary Syndrome
2
Osteoporosis
2
Fractures, Bone
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Diseases
2
Breast Cancer Female
2
Sexuality
1
Sexual Dysfunctions, Psychological
1
Neurotoxicity Syndromes
1
Neoplasm Metastasis
1
Luminal B/HER2-negative Breast Cancer
1
Leiomyoma
1
Infertility
1
Hormone-receptor-positive Breast Cancer
1
Hormone Receptor Positive Breast Carcinoma
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HR+/HER2- Early Breast Cancer
1
HR+/HER2+ Early Breast Cancer
1
Fatigue
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Stromal Tumors
1
Endometrial Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Carcinoma In Situ
1
Breast Cancer Metastatic
1
Bone Diseases, Metabolic
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Radiosurgery
79
Capecitabine
77
Oxaliplatin
74
Fluorouracil
69
Bevacizumab
69
Gemcitabine
67
Leucovorin
61
pembrolizumab
53
Nivolumab
53
Paclitaxel
48
Irinotecan
47
Radiotherapy
45
Cisplatin
44
Everolimus
38
Magnetic Resonance Spectroscopy
36
Drug Therapy
36
Docetaxel
36
Cyclophosphamide
35
Cetuximab
35
Ipilimumab
32
Carboplatin
32
Trastuzumab
31
Sunitinib
30
Sorafenib
26
Erlotinib Hydrochloride
25
Doxorubicin
23
Surveys and Questionnaires
20
Surgical Procedures, Operative
20
Specimen Handling
20
Biopsy
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm Metastasis
×
Aromatase Inhibitors
×
Clear all
NCT02188745
2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2
Completed
19 enrolled